Circulating Tumor Cells

Finding Rare Events for A Huge Knowledge of Cancer Dissemination

Edited by
April 2020
366 pages
  • ISBN978-3-03928-698-0 (Paperback)
  • ISBN978-3-03928-699-7 (PDF)

This book is a reprint of the Special Issue Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination that was published in

Biology & Life Sciences
Medicine & Pharmacology
The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system.
  • Paperback
License and Copyright
© 2020 by the authors; CC BY-NC-ND license
circulating tumor cells; circulating tumor DNA; liquid biopsy; metastatic colorectal cancer; FOLFIRINOX; circulating tumor cells; CTC; liquid biopsy; CTM; CTMat; CTC biology; CTC capture technology; metastasis; circulating tumor cells (CTCs); hepatocellular carcinoma (HCC); castration resistant prostate cancer (CRPC); epithelial-to-mesenchymal transition (EMT); fibronectin; integrin B1; SLUG; major histocompatibility complex class I (MHCI); immunomodulation; bone marrow; melanoma; disseminated tumor cells; solid cancers; single-cell analysis; enrichment and detection technologies; flow cytometry; tumor stem cells; HMB-45; CD133; locally advanced rectal cancer; circulating tumor cells; RAD23B; thymidylate synthase; chemoradioresistance; liquid biopsy; circulating tumor cells; epithelial–mesenchymal transition; stem cells; early breast cancer; prostate cancer (PCa); circulating tumor cells (CTC); liquid biopsy; circulating tumor cells; metastasis; xenograft models; breast cancer; prostate cancer; CTC; AR; AR-V7; ctRNA; exosome; circulating tumor cells; hematological cells; neutrophils; platelets; liquid biopsy; circulating tumor cells; melanoma; liquid biopsy; EPISPOT; CellSearch®; liquid biopsy; CTCs; immune checkpoint inhibitors; PD-L1 expression; NSCLC; small-cell lung carcinoma; circulating tumor cells; microfluidics; gene expression analysis; synaptophysin; chromogranin A; rovalpituzumab tesirine; leukocyte-derived extracellular vesicles; immunofluorescence imaging; EpCAM enrichment; CellSearch; EasyCount slides; ACCEPT; CTC; heterogeneity; liquid biopsy; liquid surgery; clinical utility; circulating tumor cells (CTCs); glioma; biomarker; rVAR2; malaria; enrichment and detection technologies; prostate cancer; biomarkers; circulating tumor cells; androgen receptor; ARV7; abiraterone; enzalutamide; metastasis; tumor-initiating cells (TICs); circulating tumor cells (CTCs); CTC-derived xenografts; CTC-derived ex vivo models; cerebrospinal liquid biopsy; in vivo flow cytometry; tumor biomarkers; circulating tumor cells; ctDNA; miRNA; exosomes; emboli; targeted therapy; circulating tumor cells; tumor cell dissemination; immune system; microbiome; circulating tumor cells (CTCs); clinical trials; breast cancer; CTC-based treatment decisions; circulating tumour cells; colorectal cancer; colorectal surgery; microsatellite instability; microfluidics; immunophenotyping; fish; liquid biopsy; circulating leukemia cells; circulating plasma cells; n/a